Findings of Research Misconduct, 77641-77642 [2010-31168]

Download as PDF Federal Register / Vol. 75, No. 238 / Monday, December 13, 2010 / Notices 77641 TRANSACTION GRANTED EARLY TERMINATION—Continued ET date ET req status Trans No. 20110269 20110273 20110275 20110276 20110290 20110298 FOR FURTHER INFORMATION CONTACT: Sandra M. Peay, Contact Representative or Renee Chapman, Contact Representative, Federal Trade Commission, Premerger Notification Office, Bureau of Competition, Room H– 303, Washington, DC 20580, (202) 326– 3100. By Direction of the Commission. Donald S. Clark, Secretary. [FR Doc. 2010–31092 Filed 12–10–10; 8:45 am] BILLING CODE 6750–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES Office of the Secretary Findings of Research Misconduct Office of the Secretary, HHS. Notice. AGENCY: ACTION: Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case: Sagar S. Mungekar, PhD, New York University School of Medicine: Based on the Respondent’s written admission and set forth below, the New York University School of Medicine (NYUSOM) and the Office of Research Integrity (ORI) found that Sagar S. Mungekar, PhD, former MD/PhD student in the Sackler Institute of Graduate Biomedical Sciences at NYUSOM, engaged in research misconduct in research supported by National Institute of General Medical Sciences (NIGMS), National Institutes of wwoods2 on DSK1DXX6B1PROD with NOTICES_PART 1 SUMMARY: VerDate Mar<15>2010 15:42 Dec 10, 2010 Jkt 223001 G G G G G G G G G G G G G G G G G G G G G Party name Powersport Auctioneer Holdings, LLC. Powersport Auctioneer Holdings, LLC. Religare Enterprises Limited. Landmark Partners, Inc-CT. Landmark Partners, LLC. ICV Partners II, L.P. Cargo Airport Services U.S.A. LLC. Cargo Airport Services U.S.A. LLC. TPG Star, L.P. ZS VPSI, L.P. VPSI, Inc. VPSI, L.L.C. Alliant Techsystems Inc. Sentinel Capitai Partners IV, L.P. North American Rescue, LLC. Ascent Media Corporation. ABRY Partners IV, LP. Monitronics International, Inc. Charlesbank Equity Fund VII, Limited Partnership. Behrman Capital III L.P. Peacock Holding Company, Inc. Health (NIH), grants R01 GM35769, R01 GM55624, and T32 GM07308, and National Institute of Allergy and Infectious Diseases (NIAID), NIH, grant T32 AI007180. Dr. Mungekar admitted that in his PhD thesis he ‘‘increased statistical significance of the calculated means and standards of deviation [sic] of the UV spectrophometic [sic] data presented by discarding certain experimental data and thus presented data that was falsified. In addition, as the repression ratios calculated and conclusions reached based on these data that included falsified data, those values and conclusions are fabricated. Approximately, 60–75 of the [Respondent’s] PhD research data was changed or falsified.’’ Dr. Mungekar also admitted ‘‘while doing these experiments, I did not sequence all of the constructs that I constructed, thus, I could not be certain of the exact identity of the plasmids in question.’’ ORI found that Dr. Mungekar engaged in research misconduct (42 CFR 93.103) by fabricating and falsifying data. Specifically, ORI found that Dr. Mungekar falsified five tables and five figures (Tables 2–1, 2–2, 3–1, 4–1, 4–2 and Figures 2–3, 3–1, 3–2, 4–3, and 4– 4) in his Ph.D. thesis entitled ‘‘Autoregulation of Ribonuclease E,’’ by discarding certain spectrophotometric data, to increase statistical significance, used to calculate repression ratios and RNA decay rates. Dr. Mungekar also claimed to have constructed 53 different reporter plasmids with RNase E mutants, when sequencing data did not exist to support this claim. PO 00000 Frm 00036 Fmt 4703 Sfmt 4703 Dr. Mungekar has entered into a Voluntary Settlement Agreement in which he has voluntarily agreed, for a period of three (3) years, beginning on November 22, 2010: (1) That any institution that submits an application for PHS support for a research project on which the Respondent’s participation is proposed or that uses him in any capacity on PHS-supported research, or that submits a report of PHS-funded research in which he is involved, must concurrently submit a plan for supervision of his duties to ORI for approval; the supervisory plan must be designed to ensure the scientific integrity of his research contribution; Respondent agrees that he will not participate in any PHS-supported research until such a supervision plan is submitted to ORI; (2) that any institution employing him submits, in conjunction with each application for PHS funds, or report, manuscript, or abstract involving PHSfunded research in which he is involved, a certification to ORI that the data provided by the Respondent are based on actual experiments or are otherwise legitimately derived and that the data, procedures, and methodology are accurately reported in the application or report; and (3) to exclude himself voluntarily from serving in any advisory capacity to the U.S. Public Health Service (PHS), including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant. FOR FURTHER INFORMATION CONTACT: Director, Division of Investigative E:\FR\FM\13DEN1.SGM 13DEN1 77642 Federal Register / Vol. 75, No. 238 / Monday, December 13, 2010 / Notices Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453–8800. John Dahlberg, Director, Division of Investigative Oversight, Office of Research Integrity. [FR Doc. 2010–31168 Filed 12–10–10; 8:45 am] BILLING CODE 4150–31–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Agency for Healthcare Research and Quality Priority Setting for the Children’s Health Insurance Program Reauthorization Act (CHIPRA) Pediatric Quality Measures Program— Notice of Correction On pages 75469 and 75470, Volume 75, Number 232, Federal Register notice publication dated December 3, 2010, under DATES section, the correct date is: January 14, 2011. Also, on pages 75470 and 75471, under section SUPPLEMENTARY INFORMATION all Web links that include the word: ‘‘ahrg’’ should be changed to: ‘‘AHRQ’’. Dated: December 7, 2010. Carolyn M. Clancy, Director, AHRQ. [FR Doc. C1–2010–31110 Filed 12–10–10; 8:45 am] BILLING CODE 4160–90–M DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention [Docket Number NIOSH–219] Implementation of Section 2695 (42 U.S.C. 300ff–131) of Public Law 111– 87: Infectious Diseases and Circumstances Relevant to Notification Requirements Centers for Disease Control and Prevention (CDC), Department of Health and Human Services. ACTION: General Notice and Request for Comments. AGENCY: The Ryan White HIV/AIDS Treatment Extension Act of 2009 (Pub. L. 111–87) addresses notification procedures for designated officers, medical facilities, and State and community public health officers regarding exposure of emergency response employees (EREs) to potentially life-threatening infectious diseases. The Secretary of Health and Human Services (Secretary) has delegated authority to the Director of the wwoods2 on DSK1DXX6B1PROD with NOTICES_PART 1 SUMMARY: VerDate Mar<15>2010 19:22 Dec 10, 2010 Jkt 223001 Centers for Disease Control and Prevention (CDC) to issue a list of potentially life-threatening infectious diseases, including emerging infectious diseases, to which EREs may be exposed in responding to emergencies (including a specification of those infectious diseases that are routinely transmitted through airborne or aerosolized means); guidelines describing circumstances in which employees may be exposed to these diseases; and guidelines describing the manner in which medical facilities should make determinations about exposures. CDC is seeking comment on the list of diseases and guidelines contained in this notice. DATES: Comments must be received by February 11, 2011. ADDRESSES: Comments on the content of this Notice should be in writing and addressed to: • E-mail: NIOSH Docket Officer, nioshdocket@cdc.gov. Include ‘‘Infectious Diseases’’ and ‘‘42 U.S.C. 300ff–131’’ in the subject line of the message. • Mail: NIOSH Docket Office, Robert A. Taft Laboratories, MS–C34, 4676 Columbia Parkway, Cincinnati, OH 45226. • Internet: Federal e-rulemaking portal, https://www.regulations.gov. Follow the instructions for submitting comments. Instructions: All submissions received must include the agency name and docket number for this Notice. All comments will be posted without change to https://www.cdc.gov/niosh/ docket/archive/docket219.html, including any personal information provided. For detailed instructions on submitting comments and additional information about this process, see the ‘‘Public Participation’’ heading of the SUPPLEMENTARY INFORMATION section of this document. Docket: For access to the docket to read background documents or comments received, go to https:// www.cdc.gov/niosh/docket/archive/ docket219.html. FOR FURTHER INFORMATION CONTACT: Centers for Disease Control and Prevention, Attention: James Spahr, Associate Director, Emergency Preparedness & Response, Office of the Director, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, 1600 Clifton Road, NE., Mailstop E20, Atlanta, GA 30333. Telephone (404) 498–6185 (this is not a toll-free number). SUPPLEMENTARY INFORMATION: PO 00000 Frm 00037 Fmt 4703 Sfmt 4703 Table of Contents Public Participation Introduction Definitions Part I. List of potentially life-threatening infectious diseases to which emergency response employees may be exposed. Part II. Guidelines describing the circumstances in which such employees may be exposed to such diseases. Part III. Guidelines describing the manner in which medical facilities should make determinations for purposes of section 2695B(d) [42 U.S.C. 300ff–133(d)]. Addendum: References Public Participation Interested persons or organizations are invited to participate in this request for public comments by submitting written views, arguments, recommendations, and data. Comments are invited on any topic related to this proposal. In particular, CDC invites comment on the list of infectious diseases and both sets of guidelines discussed herein. Comments submitted by e-mail or mail should be titled ‘‘Docket #219 Public Comments,’’ addressed to the ‘‘NIOSH Docket Officer,’’ and identify the author(s), return address, and a phone number, in case clarification is needed. Comments can be submitted by e-mail to nioshdocket@cdc.gov as e-mail text or as a Microsoft Word file attachment. Printed comments can be sent to the NIOSH Docket Office at the address above. All communications received on or before the closing date for comments will be fully considered by CDC in developing a final list of infectious diseases and guidelines which will be published in the Federal Register. Introduction The Ryan White HIV/AIDS Treatment Extension Act of 2009 (Pub. L. 111–87) amended the Public Health Service Act (PHS Act, 42 U.S.C. 201–300ii), including the addition of a Part G to Title XXVI, which addresses notification procedures and requirements for medical facilities, State public health officers and their designated officers regarding exposure of EREs to potentially life-threatening infectious diseases. (See Title XXVI, Part G of the PHS Act, codified as amended at 42 U.S.C. 300ff–131 to 300ff–140.) For purposes of these notification requirements, Section 2695 [42 U.S.C. 300ff–131] requires the Secretary of Health and Human Services (Secretary) to develop and disseminate: (1) A list of potentially lifethreatening infectious diseases, E:\FR\FM\13DEN1.SGM 13DEN1

Agencies

[Federal Register Volume 75, Number 238 (Monday, December 13, 2010)]
[Notices]
[Pages 77641-77642]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-31168]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary


Findings of Research Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the Office of Research Integrity 
(ORI) has taken final action in the following case:
    Sagar S. Mungekar, PhD, New York University School of Medicine: 
Based on the Respondent's written admission and set forth below, the 
New York University School of Medicine (NYUSOM) and the Office of 
Research Integrity (ORI) found that Sagar S. Mungekar, PhD, former MD/
PhD student in the Sackler Institute of Graduate Biomedical Sciences at 
NYUSOM, engaged in research misconduct in research supported by 
National Institute of General Medical Sciences (NIGMS), National 
Institutes of Health (NIH), grants R01 GM35769, R01 GM55624, and T32 
GM07308, and National Institute of Allergy and Infectious Diseases 
(NIAID), NIH, grant T32 AI007180.
    Dr. Mungekar admitted that in his PhD thesis he ``increased 
statistical significance of the calculated means and standards of 
deviation [sic] of the UV spectrophometic [sic] data presented by 
discarding certain experimental data and thus presented data that was 
falsified. In addition, as the repression ratios calculated and 
conclusions reached based on these data that included falsified data, 
those values and conclusions are fabricated. Approximately, 60-75 of 
the [Respondent's] PhD research data was changed or falsified.'' Dr. 
Mungekar also admitted ``while doing these experiments, I did not 
sequence all of the constructs that I constructed, thus, I could not be 
certain of the exact identity of the plasmids in question.''
    ORI found that Dr. Mungekar engaged in research misconduct (42 CFR 
93.103) by fabricating and falsifying data. Specifically, ORI found 
that Dr. Mungekar falsified five tables and five figures (Tables 2-1, 
2-2, 3-1, 4-1, 4-2 and Figures 2-3, 3-1, 3-2, 4-3, and 4-4) in his 
Ph.D. thesis entitled ``Autoregulation of Ribonuclease E,'' by 
discarding certain spectrophotometric data, to increase statistical 
significance, used to calculate repression ratios and RNA decay rates. 
Dr. Mungekar also claimed to have constructed 53 different reporter 
plasmids with RNase E mutants, when sequencing data did not exist to 
support this claim.
    Dr. Mungekar has entered into a Voluntary Settlement Agreement in 
which he has voluntarily agreed, for a period of three (3) years, 
beginning on November 22, 2010:
    (1) That any institution that submits an application for PHS 
support for a research project on which the Respondent's participation 
is proposed or that uses him in any capacity on PHS-supported research, 
or that submits a report of PHS-funded research in which he is 
involved, must concurrently submit a plan for supervision of his duties 
to ORI for approval; the supervisory plan must be designed to ensure 
the scientific integrity of his research contribution; Respondent 
agrees that he will not participate in any PHS-supported research until 
such a supervision plan is submitted to ORI;
    (2) that any institution employing him submits, in conjunction with 
each application for PHS funds, or report, manuscript, or abstract 
involving PHS-funded research in which he is involved, a certification 
to ORI that the data provided by the Respondent are based on actual 
experiments or are otherwise legitimately derived and that the data, 
procedures, and methodology are accurately reported in the application 
or report; and
    (3) to exclude himself voluntarily from serving in any advisory 
capacity to the U.S. Public Health Service (PHS), including but not 
limited to service on any PHS advisory committee, board, and/or peer 
review committee, or as a consultant.

FOR FURTHER INFORMATION CONTACT: Director, Division of Investigative

[[Page 77642]]

Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite 
750, Rockville, MD 20852, (240) 453-8800.

John Dahlberg,
Director, Division of Investigative Oversight, Office of Research 
Integrity.
[FR Doc. 2010-31168 Filed 12-10-10; 8:45 am]
BILLING CODE 4150-31-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.